ProMIS Neurosciences Коэффициент "короткого" интереса
Что обозначает Коэффициент "короткого" интереса в ProMIS Neurosciences?
Коэффициент "короткого" интереса ProMIS Neurosciences, Inc. является 3.26
Какое определение для Коэффициент "короткого" интереса?
Краткосрочный коэффициент - это количество проданных акций, которых нет в наличии, деленное на среднесуточный объем.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Коэффициент "короткого" интереса компаний в Health Care сектор на TSX по сравнению с ProMIS Neurosciences
Что делает ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Компании с коэффициент "короткого" интереса похож на ProMIS Neurosciences
- Arconic имеет Коэффициент "короткого" интереса из 3.25
- Nebius N.V имеет Коэффициент "короткого" интереса из 3.25
- Gigcapital2 Inc имеет Коэффициент "короткого" интереса из 3.25
- Genuine Parts Co имеет Коэффициент "короткого" интереса из 3.25
- Immersion Corp имеет Коэффициент "короткого" интереса из 3.25
- Ecopetrol SA имеет Коэффициент "короткого" интереса из 3.25
- ProMIS Neurosciences имеет Коэффициент "короткого" интереса из 3.26
- Antero Resources Corp имеет Коэффициент "короткого" интереса из 3.27
- Artelo Biosciences имеет Коэффициент "короткого" интереса из 3.27
- Artelo Biosciences имеет Коэффициент "короткого" интереса из 3.27
- PGT Innovations имеет Коэффициент "короткого" интереса из 3.27
- Masimo Corp имеет Коэффициент "короткого" интереса из 3.27
- Primaris properties including all of H&R REIT's enclosed malls имеет Коэффициент "короткого" интереса из 3.27